Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $53.2222.
SION has been the topic of a number of research analyst reports. JonesTrading increased their price objective on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Citizens Jmp reiterated a “market outperform” rating and set a $63.00 target price on shares of Sionna Therapeutics in a research report on Tuesday, May 26th. Stifel Nicolaus upped their target price on shares of Sionna Therapeutics from $44.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, May 18th. Freedom Capital cut shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 20th. Finally, Wedbush started coverage on shares of Sionna Therapeutics in a report on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price target for the company.
Get Our Latest Analysis on Sionna Therapeutics
Sionna Therapeutics Stock Performance
Sionna Therapeutics (NASDAQ:SION – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). On average, equities research analysts predict that Sionna Therapeutics will post -2.57 earnings per share for the current year.
Insider Buying and Selling at Sionna Therapeutics
In other news, Director Peter A. Thompson sold 85,918 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the transaction, the director owned 2,469,959 shares of the company’s stock, valued at $110,802,360.74. This represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 85,918 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the completion of the transaction, the director owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. This represents a 3.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 989,630 shares of company stock valued at $44,987,483 over the last three months. Insiders own 5.10% of the company’s stock.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. UBS Group AG grew its position in shares of Sionna Therapeutics by 91.1% during the 4th quarter. UBS Group AG now owns 89,177 shares of the company’s stock worth $3,669,000 after buying an additional 42,511 shares during the period. Vanguard Group Inc. lifted its holdings in Sionna Therapeutics by 3.7% in the fourth quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after buying an additional 41,797 shares during the period. Candriam S.C.A. acquired a new position in Sionna Therapeutics in the first quarter valued at approximately $9,494,000. Jennison Associates LLC boosted its stake in Sionna Therapeutics by 11.8% in the fourth quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock valued at $45,883,000 after acquiring an additional 117,903 shares during the last quarter. Finally, Eventide Asset Management LLC acquired a new stake in Sionna Therapeutics during the 4th quarter worth $26,290,000.
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.
At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.
Featured Stories
- Five stocks we like better than Sionna Therapeutics
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
